Clinical Trial Search

Primary: Determination of the Maximum Tolerated Dose (MTD) of BI 836858 — NA; NA Milligram (mg)

Primary: Number of Participants With Treatment-emergent Adverse Events (TEAT) — 1; 3; 7 Participants

Primary: Number of Participants Eligible With Pain Predominant Frozen Shoulder — 39 Participants

Primary: Primary Cohort: Percentage of Participants Experiencing Treatment-Emergent Serious Adverse Events (SAEs) — 0; 0 percentage of participants

Primary: The Number of Participants Experiencing an Unacceptable Level of Toxicity as Defined Below — 9; 6; 2; 4 Participants

Primary: Change in Number of Headache Days — -8; -6 headache days

Primary: Difference in Simulated Energy (kcal) Intake Between the Criterion Measure (Weighed Food) and Two Smartphone Apps (PortionSize and MyFitness Pal). — -150.1; 79.8 kcal

Primary: Time to Treatment Failure (TTF) — 5.5; 5.7 Months

Primary: Maximum Plasma Concentration (Cmax) of Albendazole — 43.846; 41.685; 39.737; 46.115 nanogram/millilitre (ng/mL)

Primary: Change in Mean Daily Step Counts During the 12 Month Intervention Using a Wearable Pedometer (Fitbit Watch) to Measure Step Count. — 1418; 1954; 1915; 2297 Step counts

Primary: Number of Recurrent Suicidal Events Measured by Treatment Arm — 0.66; 0.45; 0.20; 0.60 hospitalizations

Primary: Attachment & Removal Success Rate of the BD PureHub Disinfecting Caps to a Needle-free Connector — 99.9; 99.7 percentage of attachment success rate

Primary: To Evaluate the Incidence of AEs — 1; 2; 4; 2 Participants

Primary: Whole-muscle Activation — .046; .043; .040; .061 V

Primary: Week 40 to Week 52: LS Mean Change From Baseline in Best Corrected Visual Acuity (BCVA) in the Study Eye — 3.24; -0.50; 3.88; -0.27 Letters read